Appeal No. 2007-0534
Application No. 10/463,016
broadly in the specification as to encompass just about any protein/protein interaction,
the claim requirement of modulation of the active domain by the variable component is
met readily by any protein/protein binding or antigen antibody interaction.
In Silver, when the putative target interacts with the protein of interest FRET
(fluorescence resonance energy transfer) occurs between a complementary pair of
fluorescent tags attached to the two fusion proteins. Thus, two fusion protein partners
are prepared and contacted with one another such that binding occurs and a
measurable modulation (FRET) is exhibited.
Appellants have not shown and do not allege that either of the protein/protein
interactions in Silver (or Hamilton) do not result in a binding affinity of the binding
partners of at least 1 µM.
In view the above, the rejection of the claims for obviousness over Silver is
affirmed.
35 U.S.C. § 103(a)
Claims 1, 2, 5, 7-11, 15, 16, and 27-31 stand rejected under 35 U.S.C. § 103(a)
over Hamilton.
Hamilton describes a method of identifying a polypeptide that interacts with a
known polypeptide comprising a known peptide sequence linked to a first green
fluorescent protein (GFP) fragment, producing a second fusion protein comprising a test
10
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: September 9, 2013